EAU Annual Congress 2021
EAU 2021 Prostate Cancer
- EAU 2021: Treatment Options for De-Novo mHSPC: Future: Personalized Medicine for mHSPC?
- EAU 2021: Time on Treatment with Abiraterone and Enzalutamide in the Patient-Overview Prostate Cancer in the National Prostate Cancer Register of Sweden
- EAU 2021: Impact of Prior Local Therapy on Survival in mCRPC: Results from COU-AA-302 Trial
- EAU 2021: Treatment Options for De-Novo mHSPC: Local Treatment: Surgery (Primary +/- Lymph Nodes)
- EAU 2021: Treatment Options for De-Novo mHSPC: Local Treatment: Radiation Therapy (Primary +/- Lymph Nodes)
EAU 2021 Bladder Cancer
- EAU 2021: Optimal Timing of Perioperative Systemic Therapy for High-Risk Upper Urinary Tract Cancer
- EAU 2021: There Is No Role for Radical Cystectomy in cT0 After Neoadjuvant Chemotherapy
- EAU 2021: Optimal Timing of Perioperative Systemic Therapy for High-Risk Upper Urinary Tract Cancer: Adjuvant
- EAU 2021: There Is a Role for Radical Cystectomy in cT0 After Neoadjuvant Chemotherapy
- EAU 2021: Adjuvant vs Progression-Triggered Treatment with Gemcitabine After Radical Cystectomy In Platinum-Ineligible Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (AUO-AB 22-00)
EAU 2021 Kidney Cancer
- EAU 2021: Discussant: Phase 3 KEYNOTE-564 Study
- EAU 2021: Evolving Landscape of First-Line Systemic Treatment in Metastatic Renal Cell Carcinoma
- EAU 2021: Cytoreductive Nephrectomy in the Management of Metastatic Clear Cell RCC: Systemic Treatment Without or with Delayed Nephrectomy - When and How?
- EAU 2021: Cytoreductive Nephrectomy in the Management of Metastatic Clear Cell RCC: The Ideal Case - Cytoreductive Nephrectomy First
- EAU 2021: State-of-the-Art Lecture Immunotherapy-Based Management of Metastatic Clear-Cell and Variant RCC: What Can We Achieve?
EAU 2021 Press Releases
- Monitoring Proves Better Than Active Treatment for Low-Risk Prostate Cancer
- New Concept Drug Hunts down Late Stage Prostate Cancer
- Obesity Increases Survival in Advanced Prostate Cancer
- Nicotine By-Product Can Predict Recurrence of Cancer
- Magnetic Resonance Imaging (MRI) Can Cut Overdiagnoses in Prostate-Cancer Screening by Half